BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lledó GM, Carrasco I, Benítez-Gutiérrez LM, Arias A, Royuela A, Requena S, Cuervas-Mons V, de Mendoza C. Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. AIDS 2018;32:2347-52. [PMID: 30096074 DOI: 10.1097/QAD.0000000000001966] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Rial-Crestelo D, Sepúlveda MA, González-Gasca FJ, Geijo-Martínez P, Martínez-Alfaro E, Barberá JR, Yzusqui M, Casallo S, García M, Hornero CM, Espinosa-Gimeno A, Torralba M. Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents? AIDS 2020;34:427-32. [PMID: 31996593 DOI: 10.1097/QAD.0000000000002433] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 He Z, Yang D, Fan X, Zhang M, Li Y, Gu X, Yang M. The Roles and Mechanisms of lncRNAs in Liver Fibrosis. Int J Mol Sci 2020;21:E1482. [PMID: 32098245 DOI: 10.3390/ijms21041482] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
4 Søholm J, Holm DK, Mössner B, Madsen LW, Hansen JF, Weis N, Sauer AP, Awad T, Christensen PB. Incidence, prevalence and risk factors for hepatitis C in Danish prisons. PLoS One 2019;14:e0220297. [PMID: 31348813 DOI: 10.1371/journal.pone.0220297] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
5 Newsum AM, Kooij KW, Boyd A, Smit C, Wit FWNM, van der Meer JTM, Prins M, Reiss P, van der Valk M; MOSAIC study group, ATHENA observational HIV cohort and NVHB-SHM hepatitis working group. Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM. AIDS 2019;33:833-44. [PMID: 30649050 DOI: 10.1097/QAD.0000000000002138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 McIntosh AT, Wei R, Ahn J, Aouizerat BE, Kassaye SG, Augenbraun MH, Price JC, French AL, Gange SJ, Anastos KM, Goldman R. A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women. PLoS One 2021;16:e0247277. [PMID: 33705408 DOI: 10.1371/journal.pone.0247277] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Townshend-Bulson L, Roik E, Barbour Y, Bruden DJT, Homan CE, Espera HGF, Stevenson TJ, Hewitt AM, Rhodes W, Gove JE, Plotnik JN, Snowball MM, McGilvray J, Simons BC, Johnston JM, McMahon BJ. The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals. PLoS One 2021;16:e0260970. [PMID: 34855920 DOI: 10.1371/journal.pone.0260970] [Reference Citation Analysis]
8 Kronfli N, Young J, Wang S, Cox J, Walmsley S, Hull M, Cooper C, Martel-Laferriere V, Wong A, Pick N, Klein MB; Canadian Coinfection Cohort Study Investigators. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression? Clin Infect Dis 2021;73:468-77. [PMID: 32504083 DOI: 10.1093/cid/ciaa702] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
10 Corma-Gómez A, Morano L, Téllez F, Rivero-Juárez A, Real LM, Alados JC, Ríos-Villegas MJ, Vera-Méndez FJ, Muñoz RP, Geijo P, Macías J, Pineda JA; RIS-HEP13 and GEHEP 011 study groups. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. AIDS 2019;33:1167-74. [PMID: 30845068 DOI: 10.1097/QAD.0000000000002186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
11 Medrano LM, Berenguer J, Salgüero S, González-García J, Díez C, Hontañón V, Garcia-Broncano P, Ibañez-Samaniego L, Bellón JM, Jiménez-Sousa MA, Resino S. Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study. Front Med (Lausanne) 2021;8:615342. [PMID: 33598470 DOI: 10.3389/fmed.2021.615342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321 [PMID: 33244194 DOI: 10.3748/wjg.v26.i41.6304] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Fujii H, Kimura H, Hasebe C, Akahane T, Satou T, Kusakabe A, Kojima Y, Kondo M, Marusawa H, Kobashi H, Tsuji K, Ogawa C, Uchida Y, Joko K, Mitsuda A, Kurosaki M, Izumi N. Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. JGH Open. [DOI: 10.1002/jgh3.12749] [Reference Citation Analysis]
14 Atif M, Abdul Mustaan M, Falak S, Ghaffar A, Munir B. Targeting the effect of sofosbuvir on selective oncogenes expression level of hepatocellular carcinoma Ras/Raf/MEK/ERK pathway in Huh7 cell line. Saudi Journal of Biological Sciences 2022. [DOI: 10.1016/j.sjbs.2022.103332] [Reference Citation Analysis]
15 Agwa RH, Elgazzar MH, El-zayyadi IA, Saed AM, Ghannam MA, Saleh A. Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection. Egypt J Intern Med 2022;34. [DOI: 10.1186/s43162-022-00111-1] [Reference Citation Analysis]
16 Cuesta-Sancho S, Márquez-Coello M, Illanes-Álvarez F, Márquez-Ruiz D, Arizcorreta A, Galán-Sánchez F, Montiel N, Rodriguez-Iglesias M, Girón-González JA. Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. World J Hepatol 2022; 14(1): 62-79 [DOI: 10.4254/wjh.v14.i1.62] [Reference Citation Analysis]
17 Brochado-Kith Ó, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Front Immunol 2021;12:723196. [PMID: 34497613 DOI: 10.3389/fimmu.2021.723196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Márquez-Coello M, Arizcorreta A, Rodríguez-Pardo M, Illanes-Álvarez F, Márquez D, Cuesta-Sancho S, Girón-González JA. Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs. Sci Rep 2021;11:9824. [PMID: 33972651 DOI: 10.1038/s41598-021-89370-6] [Reference Citation Analysis]
19 Balmaceda JB, Aepfelbacher J, Belliveau O, Chaudhury CS, Chairez C, McLaughlin M, Silk R, Gross C, Kattakuzhy S, Rosenthal E, Kottilil S, Kleiner DE, Hadigan C. Long-term changes in hepatic fibrosis following hepatitis C viral clearance in patients with and without HIV. Antivir Ther 2019;24:451-7. [PMID: 31359874 DOI: 10.3851/IMP3327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Pokorska-Śpiewak M, Dobrzeniecka A, Marczyńska M. One-Year Outcomes after Ledipasvir/Sofosbuvir Treatment of Chronic Hepatitis C in Teenagers with and without Significant Liver Fibrosis-A Case Series Report. Viruses 2021;13:1518. [PMID: 34452383 DOI: 10.3390/v13081518] [Reference Citation Analysis]
21 Moscoso CG, Steer CJ. "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics. Hepat Med 2019;11:109-29. [PMID: 31565001 DOI: 10.2147/HMER.S213397] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Ganguly N, Chakrabarti S. Role of long non‑coding RNAs and related epigenetic mechanisms in liver fibrosis (Review). Int J Mol Med 2021;47:23. [PMID: 33495817 DOI: 10.3892/ijmm.2021.4856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Coppola C, Ciancio A, Bruno SR, Loi M, Giorgini A, Margotti M, Cossiga V, Brancaccio G, Dallio M, De Siena M, Cannizzaro M, Cavalletto L, Massari M, Mazzitelli M, De Leo P, Laccabue D, Baiocchi L, Kondili LA. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. BMC Infect Dis 2021;21:413. [PMID: 33947337 DOI: 10.1186/s12879-021-06053-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zakareya T, Elhelbawy M, Elzohry H, Eltabbakh M, Deif M, Abbasy M. Long-Term Impact of Hepatitis C Virus Eradication on Liver Stiffness in Egyptian Patients. Can J Gastroenterol Hepatol 2021;2021:4961919. [PMID: 34589447 DOI: 10.1155/2021/4961919] [Reference Citation Analysis]
25 Corma-Gómez A, Macías J, Rivero A, Rivero-Juarez A, de Los Santos I, Reus-Bañuls S, Morano L, Merino D, Palacios R, Galera C, Fernández-Fuertes M, González-Serna A, de Rojas I, Ruiz A, Sáez ME, Real LM, Pineda JA. A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure. Diagnostics (Basel) 2021;11:1501. [PMID: 34441435 DOI: 10.3390/diagnostics11081501] [Reference Citation Analysis]
26 Gavril OI, Arhire LI, Gavrilescu O, Dranga M, Barboi O, Gavril RS, Popescu R, Cijevschi Prelipcean C, Trifan AV, Mihai C. Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response. Medicina (Kaunas) 2021;57:1153. [PMID: 34833371 DOI: 10.3390/medicina57111153] [Reference Citation Analysis]